An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)

Next Previous
Trial Profile

An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Nonacog beta pegol (Primary)
  • Indications Blood coagulation disorders; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms Paradigm 6
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 20 Feb 2018 This trial has been Discontinued in Italy
    • 10 Jun 2017 Biomarkers information updated
    • 21 Feb 2017 Planned End Date changed from 1 Oct 2022 to 30 Oct 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top